Based on typical regulatory timelines and the precedent set by other GLP-1 treatments, UK availability could be expected in late 2026 or early 2027
Human skin is designed to keep things out, and GLP-1 receptor agonists are large peptide molecules that do not pass through the skin barrier easily
Opening a cold vial causes condensation to form inside, and that moisture is the enemy of stability
In humans and animals, it has shown no toxicity and good tolerability [23, 28]
Retatrutide is an investigational compound that is not FDA-approved, and PlexusDx does not sell, distribute, or prescribe Retatrutide or any other investigational peptide in this category
You can explore commonly used IV nutrients in the IV therapy ingredients library